AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

ABBV Quantitative Stock Analysis May 20, 2025 — 09:06 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Pim van Vliet.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Dividend giants are typically well-established companies with strong cash flows, resilient business models, and a long ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

This comprehensive analysis delves into AbbVie’s current position, future prospects, and the factors shaping its stock performance. Company Overview and Recent Performance AbbVie has established ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere ... ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.